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Abstract
Background: Keratin (K) 19-positive hepatocellular carcinoma (HCC) is well known to have a higher malignant
potential than K19-negative HCC: However, the molecular mechanisms involved in K19-mediated progression of
HCC remain unclear. We attempted to clarify whether K19 directly affects cell survival and invasiveness in
association with cellular senescence or epithelial-mesenchymal transition (EMT) in K19-positive HCC.
Methods: K19 expression was analysed in 136 HCC surgical specimens. The relationship of K19 with
clinicopathological factors and survival was analysed. Further, the effect of K19 on cell proliferation, invasion, and
angiogenesis was examined by silencing K19 in the human HCC cell lines, HepG2, HuH-7, and PLC/PRF/5. Finally,
we investigated HCC invasion, proliferation, and angiogenesis using K19-positive HCC specimens.
Results: Analysis of HCC surgical specimens revealed that K19-positive HCC exhibited higher invasiveness,
metastatic potential, and poorer prognosis. In vitro experiments using the human HCC cell lines revealed that K19
silencing suppressed cell growth by inducting apoptosis or upregulating p16 and p27, resulting in cellular
senescence. In addition, transfection with K19 siRNA upregulated E-cadherin gene expression, significantly inhibited
the invasive capacity of the cells, downregulated angiogenesis-related molecules such as vasohibin-1 (VASH1) and
fibroblast growth factor 1 (FGFR1), and upregulated vasohibin-2 (VASH2). K19-positive HCC specimens exhibited a
high MIB-1 labelling index, decreased E-cadherin expression, and high microvessel density around cancer foci.
Conclusion: K19 directly promotes cancer cell survival, invasion, and angiogenesis, resulting in HCC progression
and poor clinical outcome. K19 may therefore be a novel drug target for the treatment of K19-positive HCC.
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Background
Liver cancer is the second leading cause of cancer death
in men worldwide. In 2012, the incidence of liver cancer
was estimated at 782,500 and 745,500 deaths were asso-
ciated with this disease [1]. Primary liver cancers have
traditionally been classified into hepatocellular carcin-
oma (HCC) and cholangiocellular carcinoma (CCC)
originating from hepatocytes and cholangiocytes, re-
spectively [2]. In normal human liver, hepatocytes typic-
ally express keratin (K) 8 and K18, while bile duct cells
predominantly express K7 and K19 [3]. In previous
studies, a subset of HCC was observed to express K19
[3–10]. Durnez et al. [4] showed that K19-positive HCC
cells were characterized by an oval nucleus and a narrow
rim of cytoplasm, resembling non-neoplastic hepatic
progenitor cells. Given this phenotype, these researchers
hypothesized that these cells may be derived from pro-
genitor cells that have the bipotential to differentiate
into both hepatocytes and cholangiocytes. Interestingly,
K19-positive HCC had a significantly higher incidence of
early recurrence and metastasis to extrahepatic organs,
including regional lymph nodes, compared to K19-
negative (conventional) HCC [5]. Aggressive clinical be-
havior and poor prognosis of K19-positive HCC are
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thought to be due to frequent vascular invasion, poor
differentiation, or high proliferative activity of these
cells, as identified by immunohistochemical assessment
of Ki-67 [3, 6, 8]. Several studies using a tissue micro-
array or snap-frozen human HCC tissue samples dem-
onstrated that both protein and mRNA levels of the
molecules associated with epithelial-mesenchymal tran-
sition (EMT), such as vimentin, S100A4, and snail, were
highly elevated, but decreased expression of E-cadherin
was observed less frequently in K19-positive HCC [8].
The mechanisms responsible for the increased malig-
nancy of K19-positive HCC compared to conventional
K19-negative HCC have been previously explored in the
study by Govaere et al. [11]. In the present study, we
attempted to clarify whether K19 affects cell survival
and invasiveness directly in association with cellular sen-
escence or EMT in K19-positive HCC.
Methods
Patients and tissue specimens
Tissue specimens were collected from 136 patients with
HCC who underwent primary curative hepatectomy at
the Nara Medical University Hospital, during the period
between 2007 and 2012. No other treatments were given
before resection. There were 103 men and 33 women
with an age range of 29 to 84 (mean 69) years. Of the
136 HCC cases, 33 (24.3%) were positive for hepatitis B
virus surface antigen (HBsAg), 62 (45.6%) were positive
for hepatitis C virus antibody (HCVAb), and 43 (31.6%)
were negative for both HBsAg and HCVAb. The follow-
up period from surgical treatment until death due to
HCC (16 cases) or the end of this study was 30 to
2550 days (mean 1100 days).
Tissues were fixed in 10% formalin, embedded in par-
affin, cut into 3 μm sections, and mounted on silane-
coated slides. One section from each tissue was stained
with hematoxylin and eosin for histological examination.
The diagnosis of HCC was based on WHO criteria [2].
Recurrence was diagnosed by biochemical tests (tumour
marker; Alpha-fetoprotein, protein induced by vitamin K
absence or antagonist-II), sonograms, computed tomog-
raphy (CT) and magnetic resonance imaging (MRI).
Written informed consent was obtained from all patients
before treatment, according to our institutional guide-
lines. This study was approved by the institutional re-
view board.
Immunohistochemistry
Immunohistochemical study was performed on paraffin
sections using a BOND MAX Automated Immunohisto-
chemistry Vision Biosystem (Leica Microsystems, Wet-
zlar, Germany). For antigen retrieval step, Bond Epitope
Retrieval Solution 1 (citrate-based solution, pH 6.0)
(Leica Biosystems, Nussloch, Germany) was used. Anti-
bodies for immunohistochemistry are listed in Table 1.
Table 1 List of antibodies for immunohistochemistry
Primary antibody Clone Species Source Dilution Staining reagent
K19 B170 Mouse Leica Biosystems, Nussloch, Germany 1:300 DAB
E-cadherin 36B5 Mouse Leica Biosystems 1:50 AP
Ki-67 MIB-1 Mouse Life Technologies, Carlsbad, CA, USA Predilution DAB
CD31 JC70A Mouse DAKO, Glostrup, Denmark 1:200 DAB
VASH1 4A3 Mouse Abnova, Taipei, Taiwan 1:1500 DAB
Abbreviations: DAB diaminobenzidene, AP alkaline phosphatase

























Abbreviations: K keratin, FGFR fibroblast growth factor
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Double immunostaining was carried out following man-
ufacturer’s protocols using K19 and the Bond Polymer
Refine Detection kit (brownish colour, Leica Biosystems),
and E-cadherin and the Bond Polymer Refine AP-Red
Detection kit (red colour, Leica Biosystems). Bile ducts,
liver, lymph nodes, vascular endothelium, and endothe-
lial layer of the human placenta were used as positive
control for K19, E-cadherin, Ki-67, CD31, and VASH1,
respectively. Negative controls were carried out by sub-
stitution of the primary antibodies with non-immunized
mouse serum, resulted in no signal detection (Additional
file 1: Fig. S1). In this study, K19-positive HCC was de-
fined as that in which > 5% of total carcinoma cells
showed immunoreactivity against K19. E-cadherin, Ki-
67, and VASH1 positive cells were counted in 1000
cancer cells from K19-positive and K19-negative areas in
K19-positive HCC specimens. The number of blood ves-
sels in K19-positive and K19-negative HCC specimens,
identified by CD31 around cancer foci, was counted in
10 high-power fields (100×.).
Cell culture
The human HCC cell lines, HepG2, HuH-7, and PLC/
PRF/5 were purchased from Japanese Collection of
Research Bioresources Cell Bank (Osaka, Japan) and cul-
tured in RPMI supplemented with 10% FBS.
Transfection of human K19 siRNA in vitro
The cells were seeded at 105 cells per well in 6-cm
plates, and transfected with 100 nmol/L control RNA
(Santa Cruz bio, Dallas, TX, USA) or human K19 siRNAs
using Lipofectamine RNAiMAX (Life Technologies,
Carlsbad, CA, USA), in accordance with the manufactur-
er's protocol. After culturing for the indicated time, the
samples were removed and homogenized.
Quantitative real-time PCR
Template cDNA was synthesised from 1 μg of total
RNA using Primer Script RT reagent Kit (Takara, Shiga,
Japan). The quantitative real-time PCR detection was
performed using a SYBR® Premix Ex Taq kit (Takara).
The amount of actin mRNA in each sample was used to
standardise the quantity of each mRNA. The sequences
of the primers used for PCR are shown in Table 2.
Cell proliferation assay
For the cell proliferation assay, the methane thiosulfonate
(MTS) reagent was used as previously described [12–14].
All the experiments were performed in triplicate.
Cell invasion assay
In vitro invasion assays were performed using Matrigel
invasion chambers (BD Biosciences, Bedford, MA, USA)
as previously described [15]. Invading cells were counted
under a light microscope. The experiment was repeated
three times.
Senescence assay
Cells were fixed at 70% confluence and then incubated
at 37 °C overnight with staining solution containing X-
gal substrate (Senescence Detection kit, BioVision,
Milpitas, CA, USA). Cells were then observed under a
microscope for the presence of blue stain [16].
Detection of apoptosis
Liquid based cytology (LBC) was used to prepare the
cell lines for apoptosis assay by terminal deoxynucleo-
tidyl transferase-mediated deoxyuridine triphosphate-
biotin nick end labelling (TUNEL) using the ApopTag
Table 3 Comparison of clinicopathologic features between K19-
positive and K19- negative HCC (n = 136 cases)
Features K19-positive
group [n = 12
(8.8%)]
K19-negative
group [n = 124
(91.2%)]
P value
Age (years, mean ± SD) 60.1 ± 16.4 69.7 ± 9.32 0.002
Gender (male:female) (male%) 5:7 (41.7) 98:26 (79.0) 0.004
Infection
HBV (%) 4 (33.3) 29 (23.4) 0.443
HCV (%) 4 (33.3) 58 (46.8) 0.372
Non-HBV, non- HCV (%) 4 (33.3) 39 (31.5) 0.894
Cirrhosis (%) 3 (25.0) 40 (32.3) 0.606
Tumour size (mm, mean ± SD) 42.2 ± 33.3 37.0 ± 24.8 0.505
Multiple tumours (%) 2 (16.7) 14 (11.3) 0.581
TNM stage <0.001
I-II (%) 4 (33.3) 63 (50.8)
III-IV (%) 8 (66.6) 61 (49.2)
Differentiation <0.001
Well (%) 0 (0) 33 (26.6)
Moderate (%) 7 (58.3) 84 (67.7)
Poor (%) 5 (41.7) 7 (5.6)
Major vascular invasion (%) 3 (25.0) 3 (2.4) <0.001
Microvascular invasion (%) 10 (83.3) 68 (54.8) 0.063
Tumour-capsule formation (%) 5 (41.7) 98 (79.0) 0.004
Fibrous stroma (%) 5 (41.7) 41 (33.1) 0.575
Necrosis (%) 9 (75.0) 34 (27.4) <0.001
Recurrence (%) 5 (41.7) 54 (43.5) 0.977
Early recurrencea (%) 5 (41.7) 16 (12.9) 0.005
Extrahepatic recurrence (%) 5 (41.7) 13 (10.5) 0.002
Lung (%) 4 (33.3) 9 (7.3) 0.003
Bone (%) 1 (8.3) 2 (1.6) 0.130
Lymph nodes (%) 1 (8.3) 3 (2.4) 0.247
Adrenal gland (%) 0(0) 1 (0.8) 0.755
aEarly recurrence within 6 months after surgery
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in situ apoptosis detection kit (Oncor, Gaithersburg,
MD, USA) [17]. We identified cells showing darkly
stained nuclei or nuclear fragments as TUNEL-positive
apoptotic cells, and counted those in several high-power
fields.
Statistical analysis
Differences in continuous variables were analysed
using ANOVA or nonparametric tests (Mann–Whit-
ney and Kruskal–Wallis tests). All the experimental
results were analysed using the 1-way analysis of vari-
ance and Tukey’s post-hoc test. The 2-tailed student’s
t-test was used to compare 2 data points. The sur-
vival curves were calculated by the Kaplan-Meier
method, and the differences between curves were
analysed by the log-rank test. Multivariate analysis
for overall survival was performed using a Cox re-
gression model with forward stepwise selection. The
results were considered to be statistically significant
if p < 0.05.
Results
Clinicopathological features and prognosis of K19-
positive HCC
Out of the total 136 HCC cases, 12 K19-positive HCC
cases (8.8%) were examined in the present study (Fig. 1a).
Results of an analysis of the relationship between K19
expression and various clinicopathological parameters
are summarized in Table 3. K19-positive HCC predom-
inantly occurred in young, female patients. K19-positive
HCC was also associated with TNM stage, tumour dif-
ferentiation (Fig. 1b), major vascular invasion, tumour-
capsule formation as well as tumour necrosis. Early
recurrence (within 6 months after surgery) frequently
occurred in K19-positive cases. The percentages of ex-
trahepatic recurrence were 41.7 and 10.5% in K19-
positive and K19-negative cases, respectively (p = 0.002).
Among the organs, metastasis to lung was most fre-
quently observed in this study (p = 0.003). There was no
significant difference between K19 expression and HBV
or HCV infection. The non-HBV/non-HCV group and
other pathological parameters such as microvascular in-
vasion and fibrous stroma were not statistically corre-
lated with K19 expression.
Survival analysis demonstrated that patients with K19-
positive HCC had significantly poorer overall survival
than did patients with K19-negative HCC (p < 0.01)
(Fig. 1c). In contrast, there was no significant difference
in disease-free survival (p = 0.573) unless the data were
analysed during an early phase (Fig. 1d). The multivari-
ate analysis demonstrated that tumour size and necrosis





Fig. 1 Clinicopathological features of K19-positive HCC. a A sample of K19-positive HCC specimen stained with hematoxylin and eosin (HE) and
K19 immunostaining. Original magnifications: ×100 (HE), ×200 (CK19). b Poorly differentiated HCC more frequently expressed K19. c Overall
survival rate and d disease-free survival rate after primary curative hepatectomy of HCC patients with or without K19 expression. K19-positive
group had significantly lower overall survival rate than K19-negative group. Disease -free survival rate was not correlated with K19 expression.
However, during an early phase, disease -free survival curve was lower in K19-positive group than in K19-negative group. The number of patients
at risk at each time interval in K-19 positive group is showed beside each graph
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was not the case with K19 expression (Additional file 2:
Table S1).
Induction of senescence and apoptosis by K19 knockdown
In the current study, we used three human HCC cell lines,
HepG2, PLC/PRF/5, and HuH-7, which express K19
strongly, as determined by real-time PCR (Fig. 2a). K19
expression was successfully suppressed by transfection
with K19 siRNA, followed by 72-h incubation (Fig. 2b). As
shown in Fig. 2c, cell growth was significantly suppressed
by K19 knockdown in PLC/PRF/5 and HuH-7 cells but
not in HepG2 cells. When PLC/PRF/5 cells were trans-
fected with K19 siRNA, senescence was induced, as
assessed by SA-β-gal assay (Fig. 3d). Furthermore, K19 si-
lencing upregulated mRNA levels of senescence-related
genes such as p16 and p27 in PLC/PRF/5 cells (Fig. 3e). In
LBC of HuH-7 cells, the number of apoptotic cells in-
creased following K19 knockdown (Fig. 3f). Considered
together, it appears that K19 knockdown induced apop-
tosis in HuH-7 cells and senescence in PLC/PRF/5 cells
through the upregulation of p16 and p27 genes.
K19 knockdown increased E-cadherin gene expression,
and inhibited cancer invasion and angiogenesis
As stated above, cell growth was not significantly af-
fected by K19 siRNA transfection of HepG2 cells. In the
light of this result, we examined the effect of K19 knock-
down on cancer invasion and angiogenesis. Figure 3a
and c indicate that E-cadherin gene expression and
matrigel invasion capacity of HepG2 cells increased and
decreased, respectively, following K19 silencing. This
suggests that K19 could enhance cancer invasion
through decreased E-cadherin gene expression in HCC
cells. Gene expression levels of Vimentin, N-cadherin,
and snail were not affected by K19 knockdown (Fig. 3a).
The expression of the angiogenesis-related genes VASH1
and FGFR1 decreased, while that of VASH2 increased
following K19 knockdown in HepG2 cells (Fig. 3b).
However, immunohistochemical analysis of HCC speci-
mens indicated that VASH1 is strongly expressed not
only in K19-positive HCC cells, but also in K19-negative
HCC cells. VASH1 expression in HCC was not statisti-
cally correlated with K19 expression. Finally, we exam-
ined the E-cadherin expression and the HCC
proliferative activity in both K19-positive and K19-
negative areas using human K19-positive HCC speci-
mens. Double immunohistochemical staining clearly
showed that the percentages of cells positive for E-
cadherin were 27.2% in K19-positive areas and 61.7% in
K19-negative areas (p < 0.01) (Fig. 4a). In contrast, the
Ki-67 proliferative index was higher in the K19-positive
areas than in K19-negative areas (Fig. 4b). The Ki-67
Fig. 2 K19 expression and cell growth in human HCC cell lines HepG2, PLC/PRF/5, and HuH-7. a Real-time PCR analysis revealed strong expression
of K19 in all cell lines. b K19 expression in all cell lines was significantly reduced by transfection with siRNA for 72 -h. c Cell proliferation assay
using methane thiosulfonate (MTS) reagent showed suppression of K19 inhibited tumour growth in PLC/PRF/5 and Huh-7 cells but not in
HepG2 cells
Takano et al. BMC Cancer  (2016) 16:903 Page 5 of 9
proliferative index in the K19-negative area was similar
to that observed in the K19-negative HCC specimens.
Furthermore, the number of blood vessels around cancer
foci was significantly higher in K19-positive HCC speci-
mens than in K19-negative HCC specimens (Fig. 4c).
These pathological data were thus in agreement with the
results from the in vitro experiments.
Discussion
In the current study, we demonstrated that K19 pro-
moted HCC invasion, proliferation, and angiogenesis,
using in vitro experiments and immunohistochemistry.
Survival analysis revealed that patients with K19-positive
HCC had significantly poorer overall survival than did
patients with K19-negative HCC, although K19 expres-
sion was not an independent predictor in the multivari-
ate analysis for overall survival. In previous reports,
K19-positive HCC demonstrated higher invasiveness,
greater metastatic potential, and poorer prognosis than
did conventional HCC. Moreover, K19-positive HCC
specimens examined had greater vessel invasion, poor
differentiation, greater infiltrative growth, and more
extrahepatic metastasis than did K19-negative HCC
specimens [5, 8]. Although these pathological character-
istics are well documented, the biological mechanisms
involved in the aggressive behaviour of K19-positive
HCC remain unclear.
The keratins, which are intermediate filament proteins,
play several important roles within the cell. For instance,
they maintain the mechanical stability and integrity of
epithelial cells, as well as participate in several intracellu-
lar signalling pathways involved in coping with cell stress
[18]. K19 is the smallest keratin, as it lacks the non-α-
helical tail domain, which is typical of all other keratins
[19]. This protein also appears functionally dispensable




Fig. 3 Cell invasion, senescence, apoptosis and angiogenesis in HCC cell lines. a E-cadherin mRNA expression increased, whereas vimentin,
N-cadherin and snail mRNA expression was not significantly affected by K19 knockdown in HepG2 cells. b The expression of angiogenesis -related
genes VASH1 and FGFR1 decreased and that of VASH2 increased following K19 -knockdown in HepG2 cells. c Matrigel invasion assay showing
inhibition of invasion capacity of HepG2 cells transfected with K19 siRNA. d Analysis using SA-β-gal demonstrates significant induction of cell
senescence in PLC/PRF5 cells following K19 knockdown using siRNA transfection. e Senescence -related genes, p16 and p27, upregulated by K19
knockdown in PLC/PRF5 cells. f In liquid based cytology (LBC) of HuH-7 cells, the number of apoptotic cells increased following K19 knockdown
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appear normal [20]. In the present study, K19 enhanced
cancer invasion by decreasing E-cadherin expression,
and promoted cell survival by suppressing the induction
of senescence and apoptosis in HCC cells. However, the
effects of K19 were not the same across all three cell
lines used in this study, which may be due to differences
in the roles of K19, such as in cellular differentiation, in
the biological subtypes.
Ozturk et al. [21] reported that HCC cells bypass the
senescence barrier by inactivating major senescence-
related genes such as p53, p16INK4a and p15INK4. p16 is
well known to induce cell quiescence, which is tightly
associated with cell differentiation. Thus, K19 could
inhibit HCC cell differentiation by regulating p16.
Apoptosis was induced by K19 knockdown in vitro;
however, the TUNEL assay did not indicate a significant
difference in apoptosis induction between K19-positive
and K19-negative HCC areas. The percentage of Ki-67-
positive cells was statistically higher in K19-positive
HCC areas than in K19-negative areas. Considered to-
gether with the in vitro data, K19 appears to promote
HCC cell proliferation, and its suppression effectively in-
hibits tumour growth via induction of cytotoxicity.
Recently, Govaere et al. [11] reported for the first time
that K19 knockdown in HCC cell line resulted in re-
duced invasive ability. We found that K19 promotes can-
cer invasion in HepG2 cells through the downregulation




Fig. 4 Immunohistochemical analysis of human HCC specimens. a Double immunostaining for K19 (cytoplasm, brown) and E-cadherin (membrane,
red) showed that the percentage of cells positive for E-cadherin in K19-positive areas was lower than that in K19-negative areas of K19-positive HCC
specimens. b Mirror image analysis of K19 and Ki-67 indicated Ki-67 proliferative index was higher in K19-positive areas than in K19-negative areas of
K19-positive HCC specimens. c K19-positive HCC specimens had more CD31-positive blood vessels around cancer foci than did K19-negative HCC
specimens. Original magnifications: ×400 (a, left), ×200 (a, right), ×100 b, c
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N-cadherin, and vimentin was not affected by K19
knockdown. Kim et al. [8] reported that K19-positive
HCC was not associated with loss of E-cadherin expres-
sion in tissue microarray study. Using double immuno-
staining of K19 and E-cadherin, we clearly showed that
the percentage of cells positive for E-cadherin in K19-
positive areas was lower than that in K19-negative areas
of K19-positive HCC specimens. Decreased E-cadherin
expression was also shown in invasive lobular carcinoma
of the breast. In this case, E-cadherin downregulation
is caused by promoter methylation, mutations, or loss
of heterozygosity (LOH) [22]. The mechanism under-
lying the decrease in E-cadherin expression in K19-
positive HCC should be one of the goals of future
investigations.
We showed here that K19 upregulated FGFR1 and
VASH1 and downregulated VASH2 in HCC cells. More-
over, immunochemical analysis showed increased blood
vessels in K19-positive HCC. FGFR1 is a receptor tyro-
sine kinase that activates endothelial-cell proliferation
and migration [23]. Thus, it is expected that FGFR1
could be a useful therapeutic target [24]. Recent investi-
gations focused on the roles of VASH1 and VASH2 as
new regulators in angiogenesis. VASH1 is a negative
feedback regulator of angiogenesis, whereas VASH2 pro-
motes angiogenesis [25, 26]. Several studies have shown
that VASH1 expression in HCC is associated with vascu-
lar invasion and poor prognosis [27, 28]. VASH may
have different functions in HCC, and it is necessary to
analyse its organ-specific functions. Immunohistochemi-
cal analysis of HCC specimens indicated that VASH1 is
strongly expressed not only in K19-positive but also in
K19-negative HCC cells. We have not excluded the
possibility that K19 might control other signals of
VASH1-dependent angiogenesis in HCCs. K19 may
enhance tumour angiogenesis by regulating FGFR1,
VASH1, and VASH2 in HCC. Yoneda et al. [3] re-
ported that epidermal growth factor (EGF) promoted
growth and invasiveness in HCC, which was accom-
panied by increased K19 expression. EGF might be
associated with tumour growth and invasion as a
molecule downstream of K19.
Conclusions
Our findings clearly indicate that K19 has a direct role
in promoting HCC cell survival and invasion by inhibit-
ing senescence and apoptosis and downregulating E-
cadherin gene expression, respectively. In addition, K19
enhanced angiogenesis by affecting the expression of
angiogenesis-related genes such as VASH1, VASH2, and
FGFR1. Thus, K19 directly promotes cancer cell survival,
invasion, and angiogenesis. K19 could be a new target
molecule for the development of therapies against K19-
positive HCC.
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